Albany Cancer Center - Patroon Creek office has reopened. Use lower lot entrance for all appointments.
Albany Medical Center patients should continue to use upper lot entrance to check in for appointments in Suite 210.
Radiation, PET and CT patients use radiation entrance in lower lot. Learn More
Make First Appointment Refer a Patient

Clinical Trials & Research

Home / Clinical Trials & Research / View Open Trials

View Open Trials

Bladder
Breast
Cholangiocarcinoma
Head and Neck
Lung (Non Small Cell)
Lymphomas
Prostate
Renal
PH3 Ate +Cabo Renal Carcinoma
Solid Tumors
Basal Cell Carcinoma
Colorectal
Multiple Myeloma
Myelofibrosis

Bladder

  • Pembro in combo CRT vs CRT alnoe MIBC

    Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

  • Ph3 Infigratinib UC w/ FGFR3 Alt

    QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Ph3 FGFR erdafitinib urothelial

    (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Biomarker Advcd Uro Cancer and FGFR Aber

    Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Sitravatinib + Nivo Adv/Met Urothelial

    A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

  • NeoAdj Chemo +/- Nivo/IDO1inh MIBC

    A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

Breast

  • Ph 3 Chemo+Atez/Placbo TNBC

    A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo(NSABP B-59/GBG 96-GeparDouze).

  • Ph 3 Tuca/Placbo + T-DM1 HER2+

    STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • FLEX Registry: Evaluate New Gene Express

    MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Ph 2 rib + non-ster AIs HR+ HER2- aBC

    A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease (CLEE011A2207)

  • Ph3 IMMU-132 HR+, HER2- mBC

    Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)

Cholangiocarcinoma

  • Infigratinib vs Gem/Cis Cholangio

    A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Head and Neck

  • Ph3 GC4419 Oral Mucositis H&N

    ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Lung (Non Small Cell)

  • PH3 Osi +/- Platinum Chemo/Pem NSCLC

    A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2) (D5169C00001)

  • PH3 AMG 510 vs Doce a/mNSCLC

    20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C

  • PH3 Atez Tira Dura Sg 3 NSCLC

    GO41854: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)

  • Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

    D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Ph2 IMMU-132 met Solid Tumors

    A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

  • Ph3 ALK+ mNSCLC (Brigatinib-3001)

    Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • BIODESIX

    Clinical Effectiveness Assessment of VeriStrat© Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)

Lymphomas

  • Ph2 JCAR017 R/R NHL

    A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-017007)

  • Ph2 JCAR017 B-cell NHL

    A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (TRANSCEND-PILOT-017006)

  • BV in older pts w/1L cHL or PTCL

    (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Prostate

  • Abirat+pred +/- abemaciclib mCRPC

    CYCLONE 2: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Ph 2 Nivo+Ipil, Ipil mono or Caba CR mPC

    A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer (CA209-650)

  • Biomarker DNA Defect Men Prostate

    Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

Renal

  • MK-6482 Advanced Renal Cell Carcinoma

    MK6482-013: Phase 2 Study of MK-6482 in Participants with Advanced Renal Cell Carcinoma

  • PH3 Ate +Cabo Renal Carcinoma

    A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)

  • GU-102 Ph I/II Nivo + axitinib RCC

    Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

PH3 Ate +Cabo Renal Carcinoma

  • PH3 Ate +Cabo Renal Carcinoma

    A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)

Solid Tumors

  • Ph2 Erdafitinib FGFR Solid Tumors

    A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Ph 1 CPI-006+444/Pembro ST/NHL

    A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)

  • Ph2 Pemigatinib Solids FGFR

    (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Ph1/2 BLU667 thy, NSCLC, Sol tum

    A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)

Basal Cell Carcinoma

  • Ph1 CX-4945 Basal Cell Carcinoma

    A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Colorectal

  • Ph 2 Regorafenib + Anti-PD-1 MSS CRC

    An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)(20975)

Multiple Myeloma

  • Ph1/2 INCB001158 + SC Dara vs Dara SC MM

    A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma (INCB 01158-206)

  • Ph 3 Carf w/ Lena/Dex R/R MM (ARROW02)

    (Amgen 20180015) A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2).

Myelofibrosis

  • PH3 Pacritinib vs MD choice in MF

    A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)